+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors



Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors



Bulletin du Cancer 80(5): 418-430



Fourteen patients with advanced solid tumors were included in a phase I trial of recombinant human E coli derived granulocyte-macrophage colony-stimulating factor (GM-CSF) given daily subcutaneously for 10 consecutive days. Dose levels were increased from 250 micrograms/m2 to 500, 750 and 1,000 micrograms/m2. Adverse effects were mainly fever, local irritation, lethargia, arthalgia. Three patients did not complete the 10-day cycle: one patient died due to progressive disease without toxic effects related to GM-CSF, one was withdrawn because of suspicion of pulmonary embolism (not confirmed), one patient had hypotension, not recurring after treatment with GM-CSF. Although the maximum tolerated dose was not reached, the trial was stopped at 1,000 micrograms/m2, considering the satisfactory response and the high white blood cell counts observed with lower dose levels. N-fold increases of leucocyte count ranged between 4.2 and 8.2 for the first dose level (250 micrograms/m2), 4 and 10.1 for 500 micrograms/m2, 8.5 and 12.3 for 750 micrograms/m2 and 5.6 and 8.3 for 1,000 micrograms/m2. Increases of granulocyte, neutrophil and eosinophil counts had a similar pattern with a weaker response at 1,000 micrograms/m2 (two patients who completed the cycle). In contrast, even for the first three levels, no dose response relationship was shown for increases of monocytes (between 2.8 and 12 n-fold whatever the dose), or lymphocytes (between 1.7 and 10.7 n-fold whatever the dose). Decreases of platelets (between 6 and 55%) were observed, followed by a rebound after stopping treatment. No modifications of erythrocyte count were observed. Subcutaneous GM-CSF was well-tolerated up to 1,000 micrograms/m2 during a 10-day course. Hematological effects were observed from the first dose level of 250 micrograms/m2.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046970752

Download citation: RISBibTeXText

PMID: 8173195


Related references

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. Journal of the National Cancer Institute 82(8): 697-703, 1990

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. Journal of Clinical Oncology 13(9): 2272-2277, 1995

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunology ImmunoTherapy 57(2): 155-163, 2008

Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. Journal of Clinical Oncology 13(1): 79-86, 1995

Phase l/ll Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Phase i ii study of recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Bulletin du Cancer (Paris) 80(5): 418-430, 1993

A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. British Journal of Cancer 69(3): 537-540, 1994

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. Blood 73(1): 31-37, 1989

Recombinant human granulocyte macrophage colony stimulating factor gm csf a phase i trial in neutropenic aids patients. Morisset, R A (Ed ) Ve Conference Internationale Sur Le Sida: Le Defi Scientifique Et Social; V International Conference on Aids: The Scientific And Social Challenge; Montreal, Quebec, Canada, June 4-9, 1262p International Development Research Centre: Ottawa, Ontario, Canada Illus Paper 403, 1989

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndromes a Phase-I/Ii Trial. Oncology Research and Treatment 11(1): 53-55, 1988

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial. Onkologie 11(1): 53-55, 1988

Recombinant human granulocyte macrophage colony stimulating factor rhgmcsf phase i ii study in patients pts with solid tumors. Journal of Cancer Research & Clinical Oncology 116(Suppl. Part 1): 273, 1990

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Annals of Oncology 4(5): 403-407, 1993

Escalated M-Vac chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGm-Csf) in patients with advanced urothelial tract tumors. Annals of Oncology 4(5): 403-407, 1993